Department of Pneumology and Respiratory Diseases, Civil Hospital Vito Fazzi Lecce, Leece, Italy.
Section of Dermatology, Department of Biomedical Science and Human Oncology, Bari University "Aldo Moro", Piazza Giulio Cesare, Bari, Italy.
Endocr Metab Immune Disord Drug Targets. 2024;24(4):495-498. doi: 10.2174/0118715303241179230927105454.
Hereby, we describe the first case of latent mastocytosis triggered by mRNA-based vaccine to prevent COVID-19 infection.
In a 42-year-old Arabian man affected by slight, undiagnosed mastocytosis, the second dose of the COVID-19 vaccine made more blatant his latent disease. The postvaccination diagnostic iter is illustrated and the potential reasons causing the onset of the cutaneous mastocytosis are discussed.
Clinicians should keep a longer follow-up of their patients after the COVID-19 vaccination, not related to few hours, for the risk of immediate-type adverse events only.
在此，我们描述了首例由 mRNA 疫苗预防 COVID-19 感染引发的潜伏性肥大细胞增多症病例。
一名 42 岁的阿拉伯男性患有轻微、未确诊的肥大细胞增多症，第二剂 COVID-19 疫苗更明显地引发了他的潜伏性疾病。本文描述了接种疫苗后的诊断过程，并讨论了导致皮肤肥大细胞增多症发作的潜在原因。
临床医生在 COVID-19 疫苗接种后，不应仅关注数小时内的即刻不良反应风险，而应进行更长时间的随访。
